It has always been in Globtec’s interest to support and promote future-oriented technologies. For example, Developments such as fuel cells or the production of solar roof tiles that we supported already in 2009. Furthermore, it will be one of our previous goals to support developments that contribute to sustainable and better living.
Since the financing business is based on mutual trust and we have long-term business contacts with our customers and investors, we ask you to understand that due to our non-disclosure agreements, project-specific details can only be published after signing an NDA.
The company is a Hungarian biotech company focused on the development and manufacturing of biosimilar drugs for the treatment of oncologic and autoimmune diseases. The project will cover research and development (R&D) costs related to both late and early-stage development programmes, as well as capital expenditures for scale-up manufacturing in Hungary.
The proposed transaction will support R&D activities required to complete the development of the promoter’s leading biosimilar drug and to move forward other products in the pipeline. Moreover, the project will also encompass the financing of capital investments required to scale-up the manufacturing process and increase the industrial capacity of the promoter.
Scientific and technical services
GLOBTEC FINANCING EUR 8 MILLION
TOTAL COST EUR 80 MILLION
The Environmental Impact Assessment is currently under preparation by the promoter, following the guidelines of competent authorities, as it is required according to the construction plan for the expansion.